**Question:** Vaccine for meningococcal meningitis should be routinely given to -

A. children
B. elderly
C. pregnant women
D. individuals with sickle cell disease

**Core Concept:**
Meningococcal meningitis is a severe and potentially life-threatening infection caused by the bacterium Neisseria meningitidis. Vaccines are available to prevent this disease and are crucial for reducing morbidity and mortality rates. There are various types of meningococcal vaccines, such as polysaccharide, conjugate, and protein-based vaccines.

**Why the Correct Answer is Right:**
The correct answer, D. individuals with sickle cell disease, is due to the increased risk of severe meningococcal disease among these patients. Sickle cell disease is characterized by the production of abnormal hemoglobin, which leads to an increased susceptibility to bacterial infections, including meningococcal meningitis. Vaccination is essential for these patients to reduce the risk of severe disease and complications.

**Why Each Wrong Option is Incorrect:**
A. Children: Although children are indeed at higher risk for meningococcal disease, they are not the primary target population for routine vaccination. Vaccination is recommended for specific high-risk groups, such as those with sickle cell disease.
B. Elderly: While the elderly are not typically considered the primary target group for routine vaccination, they are generally at lower risk for meningococcal meningitis compared to high-risk groups.
C. Pregnant women: Although pregnant women can develop meningococcal meningitis, they are not the primary focus of routine vaccination programs. The primary target groups include high-risk individuals like those with sickle cell disease.

**Clinical Pearl:**
Vaccination is crucial for high-risk individuals to prevent severe meningococcal diseases, especially those with sickle cell disease. Routine vaccination programs primarily focus on these groups to maximize the impact on disease prevention. Informed decision-making regarding vaccination is essential for patients and healthcare providers to reduce the burden of severe meningococcal infections.